TORONTO and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of renowned…


Previous articleField Trip Health Ltd. Receives Conditional Approval to Up-List to the Toronto Stock Exchange
Next articleThe Psilocybin vs. Escitalopram Trial – Part 1